Event JSON
{
"id": "f7202f27bb4216d3348599b8c52175c18892e94c3202c98ed3e5f40e860ef2a8",
"pubkey": "3ca36882f3c0eddf401aaa2b89dbe7d0c6af1e00ee4e79a4d30db421a1038d7c",
"created_at": 1736796738,
"kind": 1,
"tags": [
[
"t",
"melanoma"
],
[
"t",
"Immunotherapy"
],
[
"t",
"oncology"
],
[
"t",
"immunology"
],
[
"t",
"Science"
],
[
"t",
"health"
],
[
"imeta",
"url https://static.mstdn.science/media_attachments/files/113/822/704/012/390/530/original/3e9f60e8559eae0f.jpg",
"m image/jpeg",
"dim 792x840",
"blurhash UMH2i.%MM|xu00xaayRjD%j[j[t7%MM{ofaz"
],
[
"proxy",
"https://mstdn.science/users/halama_immuno/statuses/113822711059342423",
"activitypub"
]
],
"content": "Small but very interesting: a new personalized T cell therapy in advanced metastatic #melanoma. Feasibility is demonstrated for this new #immunotherapy, but production time is \nstill around 19 weeks. Disease stabilisation is observed and immune responses could be measured.\n#Oncology #Immunology #science #health\n\nhttps://www.nature.com/articles/s41591-024-03418-4\n\nhttps://static.mstdn.science/media_attachments/files/113/822/704/012/390/530/original/3e9f60e8559eae0f.jpg",
"sig": "93141d3fd78a3591bd8fe38def8e6a826170f5f8dbc9c2bd063a86a0d0eafeec55366fcb6a543a4ef54906ad101559c0cd6cb729d97c700cdda7439213b1eea8"
}